Professional
Added to YB: 2024-11-27
Pitch date: 2024-11-20
SWTX [bullish]
SpringWorks Therapeutics, Inc.
+25.84%
current return
Author Info
No bio for this author
Company Info
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
Market Cap
$3.5B
Pitch Price
$37.34
Price Target
60.00 (+28%)
Dividend
N/A
EV/EBITDA
-11.96
P/E
-13.77
EV/Sales
14.41
Sector
Biotechnology
Category
growth
SpringWorks Therapeutics, Inc.: Can Two Commercial Products Be Enough of a Spring for SWTX to Work? Initiate Outperform
SWTX Outperform $60 PT: Ogsiveo for desmoid tumors showing traction; mirdametinib for NF1-PN pending approval Feb '25. Est. $900M peak Ogsiveo sales 2035, $1B mirdametinib 2035. Risks: adoption challenges, competition. Catalysts: quarterly earnings, EU approvals, pipeline data.